FDA Compounding Proposal; Visits, Product Revenue, and Preventive Dispensing Fall

1. U.S. Food and Drug Administration proposes animal-drug compounding policy for federally registered facilities

OBSERVED

On August 27, the FDA released draft Guidance for Industry #256B. ¹ It describes conditions under which FDA generally intends to exercise enforcement discretion for violations of animal-drug approval and adequate-directions-for-use requirements. ²

The proposal covers drugs made from bulk drug substances, the active ingredients used to make finished drugs. Eligible sites are FDA-registered outsourcing facilities and drug manufacturers; covered drugs would be made under current good manufacturing practice rules. ²

FDA estimates that about eight of 98 federally registered facilities performing compounding specialize in both human and animal compounding. FDA lacks their patient-specific prescription volumes and knows of no section 510(b)-registered manufacturer compounding patient-specific prescriptions. ³

For nonfood animals, the proposal covers patient-specific prescriptions and office stock, which is made without a patient-specific prescription. Copies of marketed FDA-approved or indexed drugs would require a documented medical rationale describing the clinical difference for the patient. Office stock would be limited to listed or under-review bulk drug substances. ²

Patient-specific drugs would ship directly to prescribing veterinarians, owners, or caretakers. Office stock would ship directly to the ordering clinic. Transfers through distributors, retailers, or another clinic location fall outside the proposal. ²

FDA requested comments by November 27 under docket FDA-2018-D-4533. ³

VIEWPOINT

Commercial value depends on facilities offering needed products at workable prices, order sizes, lead times, shelf lives, and delivery terms. FDA’s estimate suggests a narrow starting supplier base.

Independent practices could gain another source for time-sensitive drugs, but must weigh availability and delivered cost against added oversight, inventory demands, and recordkeeping. Corporate groups can aggregate demand and test whether site deliveries erode network savings.

Compounders and manufacturers can test product and fulfillment economics. Distributors and retailers can measure sales exposed by direct shipping. Industry professionals should track facility participation and product availability as evidence of usable capacity. Measured access gaps, delivery costs, or record burdens may justify a docket submission.

CONFIDENCE

High — FDA records confirm the draft, scope, and comment deadline. Final terms, facility participation, product supply, and prices are unknown.

ACTIONS

↑ Back to top

2. Vetsource reports deeper declines in visits, product revenue and parasite protection

OBSERVED

On September 1, Vetsource Veterinary Analytics reported U.S. year-over-year Veterinary Industry Tracker results for August 23–29. Revenue per practice rose 0.3%, while visits fell 4.9%. Service revenue rose 1.9%, while product revenue fell 5.5%. The page listed 6,413 practices. ⁴

PETMETRIX calculated that revenue per visit rose about 5.5%: (1.003 ÷ 0.951) − 1 = 5.47%. This assumes the panel’s revenue and visit measures are comparable. ⁴

Dispensed heartworm protection months fell 11.0%, while flea-and-tick months fell 9.9%. The prior report showed declines of 9.3% and 7.1%. PETMETRIX calculated that all six year-over-year results weakened by 0.9–2.9 percentage points from the prior report. The prior page listed 6,488 practices, 75 more. ^{4, 5}

VetWatch separately reported 2.2% net year-to-date revenue growth through August 29 from about 3,000 practices, with growth in all nine U.S. census divisions. ⁶

VIEWPOINT

Near-flat revenue per practice can conceal weaker clinic and product activity. Leaders need to identify which local measure needs attention: visits, product revenue per visit, protection due, or refill completion.

Practices and corporate groups can use four matched-week checks to locate persistent weakness, then target visit-recall or refill tests at affected clinics and patients.

Distributors and manufacturers can reconcile matched-account protection months with orders, shipments, fill rates, inventory and, where available, clinic sell-through. Industry professionals should keep a separate trend line for each source before interpreting market direction.

CONFIDENCE

Moderate — Dated Vetsource pages and the VetWatch email support the figures. Changing practice counts, missing weighting and panel-overlap details, and different periods limit comparison.

ACTIONS

↑ Back to top

3. American Animal Hospital Association updates canine diabetes guidance on insulin and continuous glucose monitoring

OBSERVED

On August 31, the American Animal Hospital Association (AAHA) released its 2026 AAHA Diabetes Management Guidelines for Dogs. ⁷

AAHA calls Vetsulin and neutral protamine Hagedorn (NPH) insulin good first choices. Vetsulin is U-40, or 40 units per milliliter, and is FDA approved for dogs. NPH is U-100, or 100 units per milliliter, and lacks veterinary approval. ⁸

Insulin degludec U-100 or U-200 and glargine U-300 may also be first choices. Degludec U-200 and glargine U-300 require supplied, prefilled pens. AAHA lists both without veterinary approval. ⁸

Basal insulin may require dosing every 12 or 24 hours. AAHA therefore recommends a continuous glucose monitor (CGM) at the start of basal-insulin treatment to help set each dog’s dose and schedule. ⁸

AAHA describes the document as guidance and allows variation for each patient and practice. It lists support from Adapet Medical, Boehringer Ingelheim, Dechra, and Merck Animal Health. ⁹

VIEWPOINT

The range of insulin strengths and delivery devices creates product-specific ordering, strength checks, and client education after a veterinarian selects treatment. Independent practices can align forms and stock. Corporate groups can standardize core fields while preserving medical discretion.

Continuous glucose monitoring adds sensor supply, setup, data review, and follow-up time. Measuring staff minutes and days of usable monitor data can guide appointment length, stock, and service pricing.

Distributors, e-retailers, and home-delivery providers can track availability by strength and device. Manufacturers can forecast demand from sales, backorders, fill rates, and veterinary inquiries. They should keep veterinary communications consistent with each product’s approval status. Industry professionals should separate listed options from measured adoption.

CONFIDENCE

High — AAHA states the guidance and recommendations clearly. Future use, product access, and demand still need measurement.

ACTIONS

↑ Back to top

4. Pawlicy Advisor and AAHA report owners declining care at $1,000 or less

OBSERVED

On September 1, Pawlicy Advisor and AAHA released the third edition of their pet insurance report. ¹⁰ It draws on a May–June 2026 survey of 451 U.S. veterinary professionals. ¹¹

Among respondents reporting organization type, 67.6% worked in independent hospitals and 29.1% in corporate practices; the item count was unreported. ¹¹

Of 395 respondents, 84.8% chose about $1,000 or less as the point where owners choose care that differs from their goals. The report rounded this to 85% and called it a decline in recommended care; 47.3% chose about $500 or less. ¹¹

Among 274 respondents answering both questions, those at practices that proactively recommended insurance estimated a median insured share of 7.5%. The median was 3.5% where insurance was discussed only when asked. The group difference was statistically significant (p < 0.001), the cause is unclear. ¹¹

These are professional estimates. Published results omit group sizes, test statistic, effect size and confidence interval. The methods omit the questionnaire, recruitment, mode, response rate, weighting, regional mix, distinct-practice count and possible respondent clustering within practices. The report describes Pawlicy Advisor as a licensed insurance marketplace and brokerage. ¹¹

VIEWPOINT

Lower care acceptance linked to affordability may weaken clinic revenue and downstream product demand. Clinic and consumer order records can show how cost relates to client decisions.

Wholesale and manufacturer demand also reflects patient volume, product mix and inventory timing, so it provides less direct evidence of affordability.

Carrier-neutral education presents general pet-insurance information fairly across insurers. Approved referral rules can reduce compliance risk when staff discuss insurance options with clients. The survey’s self-reported estimates and Pawlicy Advisor’s role as a pet-insurance marketplace and broker limit conclusions about cause.

CONFIDENCE

Moderate — The joint report gives question-level samples, response choices, and broad test methods. Self-reports, missing recruitment and weighting details, and Pawlicy Advisor’s commercial role limit wider use and causal claims.

ACTIONS

↑ Back to top

5. Bedinvetmab study describes atypical X-ray changes in selected safety reports

OBSERVED

On August 31, the Journal of the American Veterinary Medical Association published a retrospective study of spontaneous musculoskeletal adverse-event reports in bedinvetmab-treated dogs. Researchers searched the worldwide Zoetis Global Pharmacovigilance database from November 10, 2020, through December 31, 2025. ¹²

The search began with 36,661 adverse events reported in dogs. Screening rules flagged 7,123 records and sent 525 for expert review. Of those, 206 lacked X-rays, leaving 319 cases for first review. Experts advanced 194 cases to a second review and judged 186 consistent with abnormal periarticular bone remodeling. They created the X-ray groups after the first 40 cases, then reapplied them to those cases. ¹²

Abnormal periarticular bone remodeling is uneven growth of bone and mineralized tissue beyond a joint’s normal edge. Some of the 186 cases also showed bone loss, unusual fractures, or partial or full joint displacement. Selected voluntary reports lacked a treated-dog count and control group, leaving frequency, relative risk and cause unresolved. ¹²

Concurrent nonsteroidal anti-inflammatory drug use was reported in 118 cases (63%), but no treated-dog denominator allowed an added-risk estimate. Records were insufficient to assess label adherence in 33.9% of cases; 40.3% lacked the treatment indication. ¹²

Zoetis funded the case review and supplied the data; the paper says funding excluded writing and submission. One author serves on a Zoetis advisory board. Another disclosed Pfizer research funding from 2009 to 2015; a third reported unrelated patents. ¹²

VIEWPOINT

The PETMETRIX PULSE 2026-W27 Edition covered broader bedinvetmab safety concerns. ¹³ The study makes case reconstruction and report completeness the immediate operating focus.

Practices can reduce reconstruction time and support manufacturer follow-up by linking treatment, medicine, imaging, and safety-report records. Veterinarians retain imaging, treatment, and referral decisions.

Corporate groups can standardize records and compare completion by clinic. Distributors can route safety reports and medical questions through approved channels; order data measure demand. Product owners can use recurring intake gaps to improve reporting prompts. Industry professionals should preserve the case-selection path and favor evidence with treated-dog denominators, controls, and independent access.

CONFIDENCE

Moderate — The study documents its case flow and expert X-ray review. Selected reports, missing images, and Zoetis-held data leave frequency, risk, and cause unresolved.

ACTIONS

↑ Back to top

6. Veterinary Intelligence Company acquires Antelligence

OBSERVED

On August 27, Veterinary Intelligence Company (Vet Intel) announced that it had acquired Antelligence. The deal adds veterinary-practice data and The Fountain Report, Pet Care Weekly, and Veterinary Student Insider. Financial terms were undisclosed. ¹⁴

Vet Intel said Antelligence data covers independent and enterprise practices, corporate ownership, shelters, and the veterinary workforce. It said customers use the data for sales and marketing. It plans to deliver updates through customers’ existing systems. Vet Intel named former Antelligence chief executive Chris Kelly as chief commercial officer and said all three publications would continue. ¹⁴

That day, an authenticated Fountain Report subscriber email said the publication would remain independent and agnostic. The team and schedule would continue, subscriptions would remain unchanged, and readers would receive more personalization and proprietary-data insights. ¹⁵

VIEWPOINT

System integration may reduce data-import work, while consolidation may deepen reliance on one supplier for data and industry news. Commercial value depends on better account, territory, and launch decisions, stable access, and acceptable cost.

Independent-practice subscribers mainly face publication continuity and renewal value. Corporate groups, distributors, e-retailers, home-delivery providers, manufacturers, and other commercial operators with data licenses face price, coverage, export, feed, permitted-use, and historical-access risks.

Industry professionals can assess publication continuity through delivery, authorship, ownership disclosures, and correction handling. Measured service changes should guide renewal and reliance.

CONFIDENCE

High — The buyer’s release and an authenticated email agree on ownership, leadership, and publication continuity. Price, integration, data quality, and editorial practice need later evidence.

ACTIONS

↑ Back to top